Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 4
2017 22
2018 21
2019 9
2020 15
2021 14
2022 8
2023 14
2024 10
2025 11
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A, Wang K, Nakashoji A, Isozaki H, Shimokawa M, Kikutake C, Suyama M, Hashinokuchi A, Takada K, Takenaka T, Yoshizumi T, Mitsudomi T, Hata AN, Kufe D. Haratake N, et al. J Thorac Oncol. 2024 Mar;19(3):434-450. doi: 10.1016/j.jtho.2023.10.017. Epub 2023 Nov 3. J Thorac Oncol. 2024. PMID: 37924972 Free PMC article.
MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy.
Shigeta K, Daimon T, Hongo H, Ku SY, Ozawa H, Haratake N, Fushimi A, Nakashoji A, Bhattacharya A, Takamori S, Kono M, Rokugo M, Baba Y, Kosaka T, Oya M, Jacobi J, Long MD, Beltran H, Kufe D. Shigeta K, et al. Among authors: haratake n. JCI Insight. 2025 Jun 24;10(14):e190924. doi: 10.1172/jci.insight.190924. eCollection 2025 Jul 22. JCI Insight. 2025. PMID: 40553569 Free PMC article.
MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression.
Bhattacharya A, Wang K, Penailillo J, Chan CN, Fushimi A, Yamashita N, Daimon T, Haratake N, Ozawa H, Nakashoji A, Shigeta K, Morimoto Y, Miyo M, Kufe DW. Bhattacharya A, et al. Among authors: haratake n. Oncogene. 2024 Jul;43(28):2199-2214. doi: 10.1038/s41388-024-03068-3. Epub 2024 May 27. Oncogene. 2024. PMID: 38802648 Free PMC article.
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.
Takamori S, Haratake N, Bhattacharya A, Kikutake C, Ozawa H, Shigeta K, Nakashoji A, Isozaki H, Shimokawa M, Suyama M, Hashinokuchi A, Takada K, Toyokawa G, Yamada Y, Takenaka T, Taguchi K, Yamaguchi M, Yoshizumi T, Hata AN, Kufe D. Takamori S, et al. Among authors: haratake n. Signal Transduct Target Ther. 2025 Nov 28;10(1):389. doi: 10.1038/s41392-025-02482-7. Signal Transduct Target Ther. 2025. PMID: 41309558 Free PMC article.
MUC1-C auto-regulatory complex with EBNA1 is responsible for latent Epstein-Barr virus-associated gastric cancer progression.
Ozawa H, Wang Y, Withers HG, Haratake N, Nakashoji A, Bhattacharya A, Fushimi A, Kikutake C, Yamanoi K, White S, Wang K, Daimon T, Shigeta K, Fukuda K, Kawakubo H, Kitagawa Y, Long MD, Gewurz BE, Kufe D. Ozawa H, et al. Among authors: haratake n. Oncogene. 2025 Oct;44(38):3609-3624. doi: 10.1038/s41388-025-03519-5. Epub 2025 Aug 5. Oncogene. 2025. PMID: 40764753 Free PMC article.
MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment.
Nakashoji A, Bhattacharya A, Ozawa H, Haratake N, Shigeta K, Fushimi A, Yamashita N, Matsui A, Kure S, Kameyama T, Takeuchi M, Fukuda K, Yokoe T, Nagayama A, Hayahsida T, Kitagawa Y, Liu R, Giordano A, Jeselsohn R, Shapiro GI, Kufe D. Nakashoji A, et al. Among authors: haratake n. NPJ Breast Cancer. 2025 Apr 26;11(1):39. doi: 10.1038/s41523-025-00751-w. NPJ Breast Cancer. 2025. PMID: 40287441 Free PMC article.
MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
Yamashita N, Morimoto Y, Fushimi A, Ahmad R, Bhattacharya A, Daimon T, Haratake N, Inoue Y, Ishikawa S, Yamamoto M, Hata T, Akiyoshi S, Hu Q, Liu T, Withers H, Liu S, Shapiro GI, Yoshizumi T, Long MD, Kufe D. Yamashita N, et al. Among authors: haratake n. Mol Cancer Res. 2023 Mar 1;21(3):274-289. doi: 10.1158/1541-7786.MCR-22-0772. Mol Cancer Res. 2023. PMID: 36445328 Free PMC article.
Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
Katsumata S, Shimokawa M, Hamada A, Haratake N, Nomura K, Fujino K, Yoshikawa M, Suzawa K, Shien K, Suda K, Ohara S, Fukuda S, Kinoshita F, Hayasaka K, Notsuda H, Takamori S, Muto S, Takanashi Y, Mizuno K, Kawase A, Hayakawa T, Sekihara K, Toda M, Matsuo S, Takegahara K, Hashimoto M, Nakahashi K, Endo M, Ozawa H, Fujikawa R, Tomioka Y, Namba K, Matsubara T, Suzuki J, Watanabe H, Takada K, Hoshino H, Kaiho T, Toyoda T, Kouki Y, Shiono S, Soh J, Ohde Y. Katsumata S, et al. Among authors: haratake n. Eur J Cancer. 2024 Apr;201:113951. doi: 10.1016/j.ejca.2024.113951. Epub 2024 Feb 22. Eur J Cancer. 2024. PMID: 38417299
120 results